SCHEMBL3781508

SCHEMBL3781508

Nc1ncnc2c1c(-c1ccc(Cl)cc1)nn2C(=O)NCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 3/20 0.58
▸ FYN P06241 3/20 0.52
▸ LYN P07948 2/20 0.52
▸ BLK P51451 2/20 0.52
▸ CYP1A2 P05177 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ BTK Q06187 10/20 0.50
▸ EGFR P00533 9/20 0.49
▸ KDR P35968 2/20 0.48
▸ DAPK3 O43293 1/20 0.48
▸ RIPK2 O43353 1/20 0.48
▸ ABL1 P00519 1/20 0.48
▸ LCK P06239 1/20 0.48
▸ YES1 P07947 1/20 0.48
▸ HCK P08631 1/20 0.48
▸ PDGFRB P09619 1/20 0.48
▸ FGR P09769 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020471 0.86 CNR1 (0.44) SRCFYNLYNBLKMAPK1
SCHEMBL3779241 0.85 SRC (0.55) SRCFYNLYNBLKCYP1A2
SCHEMBL13019941 0.85 SRC (0.60) SRCFYNLYNBLKCYP1A2
SCHEMBL3790754 0.84 ALDH1A1 (0.43) SRCKMT2A
SCHEMBL13019905 0.82 SRC (0.58) SRCFYNLYNBLKCYP1A2
SCHEMBL13020475 0.81 NPSR1 (0.41) SRCFYNLYNBLKMEN1
SCHEMBL13019903 0.78 SRC (0.58) SRCFYNLYNBLKCYP1A2
SCHEMBL3788008 0.78 SRC (0.62) SRCFYNLYNBLKCYP1A2
SCHEMBL3778669 0.77 SRC (0.58) SRCFYNLYNBLKCYP1A2
SCHEMBL13019685 0.77 PIK3CD (0.73) SRCFYNLYNBLKCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
WO-2009062118-A2 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885FYN 950/4885LYN 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback